Lack of somatic ErbB2 tyrosine kinase domain mutations in hepatocellular carcinoma

Hepatology Research

Volumn 38, Issue 8, 2008, Pages 838-841

  Wong, Chiung Ing ^a   Yap, Hui Ling ^a   Lim, Seng Gee ^a   Guo, Jia Yi ^a   Goh, Boon Cher ^a   Lee, Soo Chin ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

ErbB2 mutation; Hepatocellular carcinoma; Tyrosine kinase inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; ASIAN; CAUCASIAN; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN DOMAIN; TREATMENT RESPONSE;

EID: 47649111728     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00365.x     Document Type: Article

References (14)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32.
2. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW 572016) against Her-2 overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-9.
3. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
4. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-44.
5. Cohen EEW, Lingen MW, Martin LE et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005; 11: 8105-8.
6. Liu Y, Poon RTP, Shao W et al. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma. Cancer Lett 2007; 248: 32-40.
7. Zhu BD, Yuan SJ, Zhao QC et al. Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J Gastroenterol 2005; 11: 1382-6.
8. Phillip PA, Mahoney MR, Allmer C et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. JCO 2005; 23: 6657-63.
9. Thomas MB, Chadha R, Glover K et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007; 110: 1059-67.
10. Ramanathan RK, Belani CP, Singh DA etal. Phase II study of lapatinib, a dual inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase 1 and 2 (Her2/Neu) in patients (pts) with advanced biliary tree cancer (BTC) or hepatocellular cancer (HCC). A California Consortium (CCC-P) Trial. J Clin Oncol 2006 ASCO Annual Meeting Proceedings Part I 2006; 24 (18S (June 20 Suppl.)): 4010.
11. Llover J, Ricci S, Mazzaferro V et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP) trial). J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I 2007; 25 (18S (June 20 Suppl.)): LBA.
12. Bekaii-Saab TS, Sawada T, Williams N et al. Intragenic EGFR and EGFR2 mutations in hepatobiliary tumors and potential role in predicting response to agents that target EGFR. BMC Cancer 2006; 6: 278.
13. Lee SC, Lim SG, Soo R et al. Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal carcinoma. Pharmacogenet Genomics 2006; 16: 73-74.
14. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.